fashion -WSS

fashion

author：Wikipedia 2025-09-30 19:25:59 - browse：527

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： MassMutual is introducing free genetic testing for members

WSS

H5N1 bird flu found in pasteurized milk: what we know

With measles on the rise, a personal story of a devastating disease

Cytokinetics CEO stresses company can launch heart drug on its own

Dogs on Prozac: What pet anti

MassMutual is introducing free genetic testing for members

Venture capitalist Bob Kocher on the state of digital health

Wikipedia

fashion

explore

In Memoriam: Notable people who died in 2023

Cholera vaccine supply gets boost as demand surges globally

Medicare details structure of new drug price negotiation program

With measles on the rise, a personal story of a devastating disease

Apple is now the first public company to be valued at $3 trillion

UnitedHealth financials solid despite Change Healthcare cyberattack

At least 13 dead in Texas as scorching temps continue

Dogs on Prozac: What pet anti

Guidelines to prevent youth baseball injuries need more muscle

More tobacco lobbyists active in statehouses

hotspot

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Element Biosciences CEO lays out genome sequencing strategy

Exact Sciences stock tumbles despite strong cancer detection sales

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

explore

explore

hotspot

focus